English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The present study aimed to determine the utility of 99m Tc-3PRGD 2 single photon emission computed tomography (SPECT)/computed tomography (CT) for the non-invasive monitoring of the response of integrin α v β 3 expression to anti-angiogenic treatment with bevacizumab. Bevacizumab or vehicle therapy was performed in athymic nu/nu mice bearing A549 lung tumors (moderately high integrin α v β 3 expression) or PC-3 prostate tumors (low integrin α v β 3 expression) at a dose of 1 mg twice a week. The average tumor volume was 180±90 mm 3 the day prior to baseline SPECT/CT. Longitudinal 99m Tc-3PRGD 2 SPECT/CT imaging was performed at baseline (-1 day) and at days 5 and 15. Tumors were harvested at all imaging time points for histopathological analysis with hematoxylin and eosin (H&amp;E) and immunohistochemistry staining. Results revealed a significant difference in tumor volume between vehicle- and bevacizumab-treated groups at 5 and 15 days following the start of treatment in the A549 lung model (P&lt;0.05). At 5 days after the start of therapy, the percent injected dose per gram of tissue (%ID/g) and tumor-to-muscle ratio for bevacizumab-treated A549 declined persistently (P&lt;0.05). However, for the vehicle-treated A549 model, the %ID and %ID/g value increased 5 days after the start of treatment (P&lt;0.05). For the PC-3 model, slow-growing tumors and low tumor uptake was observed throughout the study. Alterations in tumor vasculature were confirmed by histopathological H&amp;E analysis and immunohistochemistry. In conclusion, longitudinal imaging using 99m Tc-3PRGD 2 SPECT/CT may be a useful tool for monitoring the anti-angiogenic effect of bevacizumab therapy.

Integrin αVβ3‑targeted SPECT/CT for the assessment of Bevacizumab therapy in orthotopic lung cancer xenografts